CNS Pharmaceuticals (NASDAQ:CNSP) Stock Rating Upgraded by Wall Street Zen

CNS Pharmaceuticals (NASDAQ:CNSP) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

Separately, Alliance Global Partners restated a “buy” rating on shares of CNS Pharmaceuticals in a report on Thursday, May 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $300.00.

CNS Pharmaceuticals Stock Up 6.8%

CNSP stock opened at $6.48 on Friday. CNS Pharmaceuticals has a twelve month low of $4.93 and a twelve month high of $221.94. The stock’s 50 day moving average is $8.76 and its 200-day moving average is $18.87. The firm has a market capitalization of $3.69 million, a PE ratio of 0.00 and a beta of 2.64.

CNS Pharmaceuticals (NASDAQ:CNSP) last posted its earnings results on Thursday, August 14th. The company reported ($6.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($9.60) by $3.18.

Institutional Trading of CNS Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC lifted its holdings in CNS Pharmaceuticals by 90.5% during the fourth quarter. Geode Capital Management LLC now owns 387,064 shares of the company’s stock worth $47,000 after acquiring an additional 183,884 shares during the period. Integrated Wealth Concepts LLC bought a new stake in CNS Pharmaceuticals during the fourth quarter worth $30,000. Connective Capital Management LLC bought a new stake in CNS Pharmaceuticals during the fourth quarter worth $34,000. XTX Topco Ltd bought a new stake in CNS Pharmaceuticals during the fourth quarter worth $36,000. Finally, Citadel Advisors LLC bought a new stake in CNS Pharmaceuticals during the fourth quarter worth $39,000. 14.02% of the stock is currently owned by institutional investors.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.